Oxidative Stress and Mitochondrial Complex I Dysfunction Correlate with Neurodegeneration in an α-Synucleinopathy Animal Model
作者
Adriana Morales-Martínez,Paola A. Martínez-Gómez,Daniel Martínez‐Fong,Marcos M. Villegas-Rojas,Francisca Pérez‐Severiano,Miguel A. Del Toro-Colín,Karen M. Delgado-Minjares,Víctor Manuel Blanco-Álvarez,Bertha Alicia León‐Chávez,Omar Emiliano Aparicio‐Trejo,Mauricio T. Baéz-Cortés,María del Carmen Cárdenas‐Aguayo,José Luna‐Muñoz,Mar Pacheco‐Herrero,Quetzalli D. Angeles-López,Irma A. Martínez‐Dávila,Citlaltepetl Salinas‐Lara,José Pablo Romero‐López,Carlos Sánchez-Garibay,Adolfo René Méndez‐Cruz
The α-synucleinopathies constitute a subset of neurodegenerative disorders, of which Parkinson’s disease (PD) is the most common worldwide, characterized by the accumulation of misfolded α-synuclein in the cytoplasm of neurons, which spreads in a prion-like manner to anatomically interconnected brain areas. However, it is not clear how α-synucleinopathy triggers neurodegeneration. We recently developed a rat model through a single intranigral administration of the neurotoxic β-sitosterol β-D-glucoside (BSSG), which produces α-synucleinopathy. In this model, we aimed to evaluate the temporal pattern of levels in oxidative and nitrosative stress and mitochondrial complex I (CI) dysfunction and how these biochemical parameters are associated with neurodegeneration in different brain areas with α-synucleinopathy (Substantia nigra pars compacta, the striatum, in the hippocampus and the olfactory bulb, where α-syn aggregation spreads). Interestingly, an increase in oxidative stress and mitochondrial CI dysfunction accompanied neurodegeneration in those brain regions. Furthermore, in silico analysis suggests a high-affinity binding site for BSSG with peroxisome proliferator-activated receptors (PPAR) alpha (PPAR-α) and gamma (PPAR-γ). These findings will contribute to elucidating the pathophysiological mechanisms associated with α-synucleinopathies and lead to the identification of new early biomarkers and therapeutic targets.